Literature DB >> 27748716

Pathophysiology of Immediate Reactions to Injectable Gadolinium-based Contrast Agents.

Tara F Carr1.   

Abstract

OBJECTIVE: The aim of this paper was to review the classification of adverse drug reactions, highlight the known pathophysiology of immediate hypersensitivity reactions, and discuss the utility of diagnostic testing for immunologically mediated immediate reactions to gadolinium-based contrast agents (GBCAs).
METHODS: Current literature on immediate reactions to GBCA was reviewed and summarized.
RESULTS: Adverse drug reactions to GBCA are rare, and can be attributed to physiologic, immunologic, and nonimmunologic processes. When immunologic reaction is suspected, particularly in the case of severe reactions, skin testing may be useful to confirm allergy and identify alternative agents for subsequent studies.
CONCLUSION: As GBCAs are widely used for the diagnosis and monitoring of disease, the incidence of adverse drug reactions to GBCA warrants ongoing development of approaches to diagnosis and avoidance of these adverse events.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27748716     DOI: 10.1097/RMR.0000000000000108

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  3 in total

1.  Drug-induced anaphylactic reactions in children: A retrospective analysis of 159 validated spontaneous reports.

Authors:  Bernhardt Sachs; Diana Dubrall; Wilma Fischer-Barth; Matthias Schmid; Julia Stingl
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-01-31       Impact factor: 2.890

2.  Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents.

Authors:  Azadeh Hojreh; Andreas Peyrl; Aleksandra Bundalo; Zsolt Szepfalusi
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

3.  Abbreviated MRI protocol for colorectal liver metastases: How the radiologist could work in pre surgical setting.

Authors:  Vincenza Granata; Roberta Fusco; Antonio Avallone; Antonino Cassata; Raffaele Palaia; Paolo Delrio; Roberta Grassi; Fabiana Tatangelo; Giulia Grazzini; Francesco Izzo; Antonella Petrillo
Journal:  PLoS One       Date:  2020-11-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.